Amgen builds its digital health capabilities through investment in leading digital health incubator

AmgenAmgen (Europe) GmbH, an affiliate of Amgen Inc. (NASDAQ:AMGN) (collectively, "Amgen") today announced an investment in eHealth Ventures, an Israel-based digital health incubator. The investment reflects Amgen's commitment to serving patients by driving innovation and sustainable healthcare through technology discovery, and recognizes the importance of Israel as a source of innovation in eHealth and digital technologies. Additional investors include Israeli HMO Maccabi Healthcare Services and Amgen's Israeli distributor Medison Pharma Ltd. Amgen will be the lead biopharmaceutical investor.

"Engaging in multi-stakeholder partnerships will drive innovation and enable us to deliver additional value to patients and the healthcare community, beyond our life-saving medicines," said Corinne Le Goff, senior vice president, Amgen Europe. "This collaboration with eHealth Ventures is a natural fit for Amgen and will help us expand our digital health pipeline and support the growth of valuable health technology to improve the lives of patients across the world."

"We are proud to have Amgen, a global market leader, join the eHealth Ventures unique consortium together with Maccabi Healthcare Services, Cleveland Clinic and Medison Pharma. This addition will provide a new strategic element to our screening process and build significant value to our portfolio companies. Having Amgen on board will deliver invaluable assets and know-how in many of the digital health innovation aspects, including market input, commercialization of R&D, business modeling, go-to-market strategies and more," said Talor Sax, eHealth Ventures Incubator chief executive officer. "We are grateful to our partner Medison Pharma, for realizing this vision and making this partnership a reality."

About eHealth Ventures
eHealth Ventures, a consortium of world-class organizations and investors active in the field of digital health, was launched in March of 2016 with Israeli government backing. The consortium, which comprises Cleveland Clinic, a leading US hospital, Maccabi Healthcare Services, Israel's leading and most advanced health provider, and Medison Pharma, Israel's largest independent specialty pharmaceutical company and Amgen's distributor in Israel, aims to invest in 40 new companies over an eight year period.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

SMi Group announces the 9th Annual RNA Therapeutic…

21 - 22 February 2018, London, UK. As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]